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Unraveling the Driving Forces Behind
Bacterial Infection
Jenna Bouvang, Utah State University | Dr. Nicholas Dickenson, Utah State University

Methods

Results

Shigella flexneri is a water-borne Gramnegative bacterial pathogen which causes
shigellosis, a severe form of dysentery that
is hallmarked by massive fluid loss and
hemorrhaging of the intestines. Shigella is
responsible for a least 90 million infections
and more than 100,000 deaths per year.
The recent emergence of multidrugresistant Shigella strains underscores the
need for alternative treatment options
which can only be achieved with a better
understanding of the means by which
Shigella infects human cells.
Shigella relies on a Type Three Secretion
System (T3SS) to inject proteins into host
cells and ultimately cause infection. We
recently identified the T3SS protein Spa47
as an enzyme that provides the energy for
protein secretion. Here we solved the
crystal structure of Spa47, generated and
activated oligomeric model, and identified
key amino acid residues necessary for T3SS
function and Shigella infection.

• A series of Spa47 mutants were
cloned, expressed, and purified.
• The activity of each of these mutants
were measured using a radioactive
ATP hydrolysis activity assay
• The Spa47Δ1-79 mutant was crystalized
and the structure was determined
using X-ray diffraction.
• A complete series of phenotypic
studies were performed to determine
the role of Spa47 activation in Shigella
infection.

• The first crystal structure of Spa47
was solved and used to generate an
activated Spa47 model (see Figure 1).
• Each of the mutations resulted in an
elimination of ATP hydrolysis activity.
• Shigella harboring the inactive Spa47
mutations could not infect host cells.
• The loss of infection capabilities
resulted from the inability of Shigella
to assemble a proper T3SS apparatus.

Figure 1 – Cartoon depiction of the Shigella T3SA, the
solved structure of Spa47, and our model of activated
Spa47
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Introduction

Figure 2 – Effects of
engineered Spa47 mutations
on Shigella infection
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Conclusions
ATPases play a critical role in the energetics
and regulation of T3SS infection-mediated
bacterial infections. This first structurefunction characterization of Spa47
provides critical insight into the regulation
of Shigella infection which clearly requires
Spa47 oligomerization to activate the
enzyme. It is our hope that these and
future studies will support the
development of much needed nonantibiotic based treatments for shigellosis
and other related diseases.

